Day: May 17, 2021

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study

  THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average...

Orchestra BioMed™ Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy™

GigCapital2 Announces Effectiveness of Registration Statement and Special Meeting Date for Proposed Business Combinations with UpHealth Holdings, Inc. and Cloudbreak Health, LLC

Special meeting of GigCapital2’s stockholders to approve the proposed business combinations with UpHealth Holdings, Inc. and Cloudbreak Health, LLC to...

error: Content is protected !!